We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Milestone Pharmaceuticals Inc | NASDAQ:MIST | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.05 | -3.03% | 1.60 | 1.52 | 1.78 | 1.6671 | 1.575 | 1.65 | 101,267 | 00:54:06 |
MONTREAL and CHARLOTTE, N.C., Nov. 23, 2020 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:
A replay of the pre-recorded Piper Sandler fireside chat is currently available in the News & Events section of Milestone's website at www.milestonepharma.com, and a live webcast of the Evercore fireside chat can be accessed in the same section of Milestone's website. An archived replay of the webcasts will be available on the same website for approximately 90 days following the presentations.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow the Company on Twitter at @MilestonePharma.
Contact
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-upcoming-investor-conferences-301178279.html
SOURCE Milestone Pharmaceuticals, Inc.
Copyright 2020 Canada NewsWire
1 Year Milestone Pharmaceuticals Chart |
1 Month Milestone Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions